Supplementary Information for
“Integrated analyses prioritize therapies for PIK3CA-mutant breast cancer and reveal a pro-survival role for p21 in drug resistance”
Hon Yan Kelvin Yip1,2, Sung-Young Shin1,2, Annabel Chee1,3, Ching-Seng Ang4, Fernando Rossello5, Lee Hwa Wong1, Lan K. Nguyen1, * , and Antonella Papa1,6,* 
1Cancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria 3800, Australia.
4Bio21 Mass Spectrometry and Proteomics Facility, The University of Melbourne, Parkville, VIC 3010, Australia.
5 Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
2These authors contributed equally.
3Present address: Centre for Muscle Research, Department of Anatomy and Physiology, The University of Melbourne, Melbourne, VIC 3010, Australia
6Lead contact
*Corresponding author: lan.k.nguyen@monash.edu (L.K.N), antonella.papa@monash.edu (A.P.)

How to run:
1) Download all the files and save them to your local drive.
2) Execute 'run_master_code'.
3) Choose a number you want to reproduce:
4) [1] Figure 1B: Comparison of model predictions and experimental data
5) [2] Figure S1D: Model validation using independent experimental data
6) [3] Figure 1E: Model prediction of signaling response to BYL719
7) [4] Figure 2A-C (S3C): Computational model (parental) predicts synergistic drug combinations
8) [5] Figure 2D-F (S3D): Computational model (resistant) predicts synergistic drug combinations
9) [6] Figure 2G: Simulation of phospho-AKT, phospho-S6, and cyclin D1 levels to BYL719 and GSK2334470
10) [7] Figure 4AB: Model predictions assessing inter-dependency between p21 levels
11) [8] Figure 7D: Model simulations (the phenotypic model) of drug synergism for 25 drug pairings co-targeting PI3K 



